

Termination of At-the-Market Subscription Deed

Melbourne, Australia; 8 October 2026: [Cynata Therapeutics Limited](#) (ASX: “CYP”, “Cynata”, or the “Company”), advises that it has given notice to terminate its At-the-Market Subscription Deed (“ATM”) with Acuity Capital, with effect from 14 October 2026.

As announced on [22 August 2025](#), the ATM provided Cynata with up to \$7,500,000 of standby equity capital. As security for the ATM, the Company agreed to place 11,500,000 fully paid ordinary shares in the Company from its Listing Rule 7.1 capacity at nil cash consideration to Acuity Capital.

As announced on [23 January 2026](#), the Company utilised the ATM to raise \$1,204,000 through the set-off of 4,300,000 shares, leaving Acuity Capital with a balance of 7,200,000 shares.

Under the ATM, following termination, the Company may, subject to consultation with Acuity Capital and shareholder approval, buy back and cancel the 7,200,000 shares held as security, for nil cash consideration. It is the Company’s intention to proceed with the buy back and cancellation.

No termination fee or penalty is payable by Cynata and no consideration is payable to Acuity Capital for the shares to be bought back and cancelled.

ENDS-

Authorised for release by the Board of Directors

CONTACT: investors@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited’s (ASX: CYP) core asset is currently the Cymerus™ platform, which offers a genuinely differentiated approach to manufacturing mesenchymal stromal cells at commercial scale from a single, consistent cell source. The Board is now focused on evaluating the future development pathways available for this technology, and the broader strategic options open to the Company. This includes seeking opportunities to realise value from the Cymerus™ technology and obtaining rights to new assets.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, [Automic Pty Ltd](#).